menu search download flag tag book folder external-link phone envelope angle-left angle-right angle-up angle-down close notifications

Care / Clinical Trial

HIV/TB co-infection

  • MTB-CAMELIA (ANRS 12278)
    The CAMELIA trial (ANRS 1295) showed a markedly improved survival when ART was initiated at 2 weeks compared to 8 weeks after TB treatment onset in HIV-infected adults with CD4 ≤ 200/mm3 (Blanc et al., NEJM, 2011). The main cause of mortality was TB (Marcy et al., CID, 2014) and TB-associated IRIS was very common (Laureillard et al., AIDS, 2013). In this CAMELIA nested-study, we want to investigate the association of Mycobacterium tuberculosis (Mtb) genotypes with the severity of TB and with different outcomes such as mortality and occurrence of TB-IRIS. All the Mtb isolates are genetically characterized and will be analyzed with the clinical data.
  • STATIS (ANRS 12290):
    A multicentre (Cambodia, Côte d’Ivoire, Uganda, Vietnam) randomized clinical trial to compare the 24-week risk of death and occurrence of invasive bacterial infection between 2 strategies in HIV-1 infected adults who ART with CD4 <100/mm3: (i) continuous extensive TB screening during follow-up each time the patient present with symptoms, versus. (ii) systematic empirical TB treatment started 2 weeks before ART initiation.
  • REFLATE TB-2 (ANRS 12300):
    A multicentre (Brazil, Côte d’Ivoire, France, Mozambic, Vietnam) randomized clinical trial to assess the non-inferiority of Raltegravir compared with Efavirenz, both in combination with Lamivudine and Tenofovir, in ART-naïve HIV-1-infected patients receiving rifampin for TB treatment.


Hepatitis C

FIBRHIVIET-ANRS 12262: In Haiphong (Vietnam), we showed that more than 40% of HIV/HCV co-infected patients successfully treated with antiretroviral treatment presented liver fibrosis and needed urgently an unavailable treatment for chronic hepatitis C (Nguyen Truong Tam et al., PLOS ONE, 2016).

Nicolas Nagot

Scientific supervisor

Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque tellus elit, condimentum eu lacus sit amet, luctus scelerisque libero. Sed hendrerit eget lectus et efficitur. Cras suscipit viverra felis sed sollicitudin. Nullam rhoncus tempor pharetra. Integer vitae porttitor neque. Quisque vestibulum tortor a turpis ultricies lobortis. Aenean pretium turpis sagittis lectus tincidunt varius. Aliquam rutrum enim lacus, quis facilisis neque viverra eget. Quisque accumsan, risus id congue fermentum, quam orci pharetra sapien, ut tincidunt velit magna ac mi.

Publications | Email